News stories about OncoSec Medical (NASDAQ:ONCS) have been trending somewhat positive this week, according to Accern Sentiment. The research group identifies positive and negative media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. OncoSec Medical earned a news sentiment score of 0.17 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 46.360369796592 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
A number of research firms have recently issued reports on ONCS. ValuEngine upgraded shares of OncoSec Medical from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. HC Wainwright set a $4.00 price target on shares of OncoSec Medical and gave the company a “buy” rating in a research report on Wednesday, May 9th. Finally, Maxim Group set a $5.00 price target on shares of OncoSec Medical and gave the company a “buy” rating in a research report on Tuesday, May 8th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. OncoSec Medical has a consensus rating of “Buy” and an average price target of $4.50.
Shares of OncoSec Medical stock traded up $0.08 during trading on Wednesday, hitting $1.43. 15,783 shares of the company were exchanged, compared to its average volume of 449,457. OncoSec Medical has a fifty-two week low of $0.88 and a fifty-two week high of $2.95. The company has a market capitalization of $72.24 million, a P/E ratio of -1.35 and a beta of 3.03.
OncoSec Medical Incorporated, a biotechnology company, engages in developing DNA-based intratumoral immunotherapies in the United States. The company's investigational technology, ImmunoPulseis designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as plasmid encoded IL-12 (tavokinogene telseplasmid or tavo) for the treatment of cancer.
Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.